<DOC>
	<DOCNO>NCT01038284</DOCNO>
	<brief_summary>Pulmonary arterial hypertension ( PAH ) severe pulmonary vascular affection , treatment evolve last year , improve quality life . However , adherence treatment assess patient . The investigator develop collaborative care model involve clinical pharmacist PAH . The objective work evaluate impact model care medication error adverse event , quality life clinical criterion . This randomized multicentre control study include approximately 100 PAH patient ( NYHA II IV ) . After inclusion , patient receive either collaborative care include consultation specialized pharmacist nurse , classic follow-up . Each patient follow 18 month date inclusion . The investigator hope show positive impact collaborative care model PAH . More specifically , investigator aim show interest long-term patient education improve patient safety relate drug , also quality life , preliminary data usual clinical criterion .</brief_summary>
	<brief_title>Multidisciplinary Collaboration Care Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Age 18 ; Pulmonary arterial hypertension ( NYHA II IV ) ; Any specific PAH treatment oral anticoagulant . Patients 18 protected law ; Patients speak/understand French ; Pregnancy ; Patients enrol clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Patient Education</keyword>
	<keyword>Drug Toxicity</keyword>
</DOC>